Anti-Hypertensive Drugs - Uganda

Uganda

The Anti-Hypertensive Drugs market in Uganda is expected to witness a significant increase in revenue, with projections indicating that it will reach US$5.24m in 2024.
Furthermore, the market is anticipated to experience a steady annual growth rate (CAGR 2024-2028) of -0.14%, leading to a market volume of US$5.21m by 2028.
It is worth noting that in terms of global comparison, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Uganda's anti-hypertensive drugs market is witnessing an increasing demand due to the rising prevalence of hypertension among its population.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Uganda has been steadily growing over the past few years.

Customer preferences: Uganda has a high prevalence of hypertension, with an estimated 26% of adults suffering from the condition. As a result, there is a high demand for anti-hypertensive drugs in the country. Patients prefer drugs that are affordable and easily accessible, as well as those that have minimal side effects.

Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in Uganda is the increasing availability of generic drugs. This has led to a reduction in the cost of drugs, making them more affordable for patients. Additionally, there has been an increase in the number of pharmacies and drug stores in the country, which has made it easier for patients to access these drugs. Another trend is the increasing use of combination therapy, where patients are given a combination of two or more drugs to manage their hypertension.

Local special circumstances: One of the unique challenges in the Anti-Hypertensive Drugs market in Uganda is the prevalence of counterfeit drugs. This is a major concern for patients, as these drugs are often ineffective and can have harmful side effects. The government has taken steps to address this issue, including increasing regulation and enforcement measures.

Underlying macroeconomic factors: The Ugandan economy has been growing steadily over the past few years, which has led to an increase in disposable income for many households. This has contributed to the growth of the Anti-Hypertensive Drugs market, as patients are now able to afford these drugs. Additionally, the government has been investing in the healthcare sector, which has led to an improvement in healthcare infrastructure and services. This has also contributed to the growth of the market, as patients are now able to access healthcare facilities more easily.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.